Optimised T cell targeting of cancer

• Research type

  Research Study

• Full title

  A study to investigate methods of optimising T cell therapies in cancer.

• IRAS ID

  169632

• Contact name

  John Bridgeman

• Contact email

  j.bridgeman@cellulartherapeutics.co.uk

• Duration of Study in the UK

  4 years, 11 months, 30 days

• Research summary

  We are looking at developing novel, and improving existing, T cell therapies for cancer. For this project we will be investigating new methods of producing patient-tailored therapies using white blood cells and assessing ways of identifying patients who are most likely to respond to this treatment.

• REC name

  North West - Greater Manchester East Research Ethics Committee

• REC reference

  15/NW/0341

• Date of REC Opinion

  24 Apr 2015

• REC opinion

  Favourable Opinion